Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Showing 1 to 15 of 15

TitleReference numberPublishedLast updated
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyTA1126
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)TA1124
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)TA1125
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessmentHTG766
Digital self-help for eating disorders: early value assessmentHTG768
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)TA1123
Balloon cryoablation for Barrett's oesophagusHTG767
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Acoramidis for treating transthyretin amyloidosis with cardiomyopathyTA1121
Suspected cancer: recognition and referralNG12
Avelumab with axitinib for untreated advanced renal cell carcinomaTA1120
Overweight and obesity managementNG246
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA1119

Results per page

  1. 10
  2. 25
  3. 50
  4. All